The Enigma of Type 3c Diabetes in Chronic Pancreatitis
DOI:
https://doi.org/10.17140/poj-1-106Keywords:
pancreatitis, hemochromatosis, cystic fibrosis, fibrocalculousAbstract
Pancreatogenic or Type 3c diabetes (T3cDM) is relatively a new entry in the complex world of diabetes study. While the general population and physicians are well aware of type 1 and type 2 diabetes mellitus, as evidenced by numerous study groups and the reams of guide-lines on diagnosis and treatment of type 1 and type 2 diabetes mellitus, relatively much less is known, considered and documented about diabetes mellitus that occurs secondary to pancreatic diseases. A casual search of Pubmed reveals less than 100 entries on type 3c diabetes. This may be because physicians earlier considered type 3c diabetes to be of rare occurrence and thus a condition rarely considered in everyday practice. Yet, recent data on type 3c diabetes (T3cDM) showed that it might be more common than generally thought. Studies also propose that this clinically important condition might be consistently under and misdiagnosed in routine clinical practice.
References
Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015; 518: 495-501. doi: 10.1038/nature14169
Witkiewicz AK, McMillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and thera-peutic targets. Nature communications. 2015; 6: 6744. doi: 10.1038/ncomms7744
Wang L, Tsutsumi S, Kawaguchi T, et al. Whole-exome sequencing of human pancreatic cancers and characterization of ge-nomic instability caused by MLH1 haploinsufficiency and complete deficiency. Genome research. 2012; 22: 208-219. doi: 10.1101/ gr.123109.111
Quilichini E, Haumaitre C. Implication of epigenetics in pancreas development and disease. Best Practice & Research Clinical Endocrinology & Metabolism. 2015; 29: 883-898. doi: 10.1016/j.beem.2015.10.010
Roy DM, Walsh LA, Chan TA. Driver mutations of cancer epigenomes. Protein & Cell. 2014; 5: 265-296. doi: 10.1007/s13238- 014-0031-6
Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nature Reviews Genetics. 2012; 13: 484- 492. doi: 10.1038/nrg3230
Guo M, Jia Y, Yu Z, et al. Epigenetic changes associated with neoplasms of the exocrine and endocrine pancreas. Discovery Medicine. 2014; 17: 67-73.
Park JY, Helm J, Coppola D, Kim D, Malafa M, Kim SJ. MicroRNAs in pancreatic ductal adenocarcinoma. World Journal of Gastroenterology. 2011; 17: 817-827.
Saha A, Wittmeyer J, Cairns BR. Chromatin remodelling: the industrial revolution of DNA around histones. Nature Reviews Molecular Cell Biology. 2006; 7: 437-447. doi: 10.1038/nrm1945
Hakimi AA, Chen YB, Wren J, et al. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. European Urology. 2013; 63: 848-854.
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Pancreas (POJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.